|Biodelivery Sciences International Inc., of Raleigh, N.C.||Belbuca||Buprenorphine buccal film||Pain management||Results showed its effect on respiratory drive was comparable to placebo at all doses tested|
|Huya Bioscience International, of San Diego||HBI-3000||Multi-ion channel blocker||Cardioversion of atrial fibrillation||Results showed it was well-tolerated with no dose-limiting adverse events or arrhythmias observed|
|Sorrento Therapeutics Inc., of San Diego||Resiniferatoxin||Binds to TRPV1 receptors||Intractable cancer pain||An interim analysis of an ongoing phase Ib study showed no dose-limiting toxicities or notable adverse events unrelated to progression of underlying disease were encountered for any of the subjects; the most common adverse event was transient post-procedural pain in 7 of 14 subjects (50%)|
|Antibe Therapeutics Inc., of Toronto,||ATB-346||Anti-inflammatory/analgesic agent||Osteoarthritis||Last patient was enrolled in the phase IIb dose-ranging, efficacy study|
|Galera Therapeutics Inc., of Malvern, Pa.||Avasopasem manganese (GC-4419)||Superoxide dismutase mimetic||Severe oral mucositis||Results from 2-year follow-up of patients with head and neck cancer in a phase IIb trial showed tumor outcomes were maintained in both avasopasem manganese dose groups compared to placebo, and outcomes for the 90-mg dose group were comparable to placebo across all 4 measures – overall survival, progression-free survival, locoregional control and metastasis-free survival|
|Ironwood Pharmaceuticals Inc., of Boston||IW-3718||Gastric-retentive formulation of bile acid sequestrant||Refractory gastroesophageal reflux disease||Phase IIb data published in Gastroenterology showed that a 1,500-mg dose given twice daily with a proton pump inhibitor (PPI) significantly reduced heartburn severity and reduced frequency of regurgitation vs. a PPI alone|
For more information about individual companies and/or products, see Cortellis.